Pure Global AI
NCT06247839Not yet recruiting

The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder

Massachusetts General HospitalPhase 3ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Major Depressive Disorder
Drug/Device/Intervention
Psilocybin
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Massachusetts General Hospital
Timeline & enrollment
Phase
Phase 3
Start date
Apr 01, 2024
End date
Jun 30, 2026
Enrollment
20 participants
Primary outcome

Change in Massachusetts General Hospital Rumination Questionnaire (MGH-RQ),Change in Resting-State Functional Connectivity,Change in Self-Attribution Task performance,Change in Task-Based Activity during Self-Attribution Task

Summary

This open-label functional Magnetic Resonance Imaging (fMRI) study will assess the effects of
 a single dose of psilocybin on rumination and the neural correlates of rumination in
 individuals with major depressive disorder.

ICD-10 classifications
Recurrent depressive disorderRecurrent depressive disorder, unspecifiedDepressive conduct disorderOther recurrent depressive disordersRecurrent depressive disorder, current episode moderate
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06247839
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06247839 through Pure Global AI's free database. This Phase 3 trial is sponsored by Massachusetts General Hospital and is currently Not yet recruiting. The study focuses on Major Depressive Disorder. Target enrollment is 20 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.